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Essential thrombocythaemia (ET) is a myeloproliferative neoplasm
(MPN) characterised by megakaryocyte hyperplasia and thrombo-
cytosis. From the genetic perspective, ET patients harbour
mutations in JAK2 (50–60%), CALR (15–30%) and MPL (1–5%)
genes.1 These frequencies have been determined in most studies
using DNA obtained from isolated granulocytes or from whole
blood, but, there is little information regarding the prevalence of
these mutations when platelets are analysed. Some previous
studies have reported that in ~ 10% of ET patients the JAK2V617F
mutation was only detectable when platelets are analysed, in
agreement with the predominant involvement of the
megakaryocytic-platelet lineage in this disease.2,3 In contrast,
some studies suggested no differences in the frequency of
JAK2V617F mutation between platelets and granulocytes when
allele specific RT-PCR and RFLP analysis of platelet RNA was
performed.4,5 In this sense, our group has observed a higher
JAK2V617F allele burden in platelets when compared with
granulocytes in ET patients, although no differences were found
in the number of mutated cases.6 Concerning mutations in MPL
gene, the analysis of 82 ET patients showed in two cases the
presence of MPLW515L in platelets but not in granulocytes, T-cells
or erythroid colonies.3 Finally, there is scarce information
regarding the presence of CALR mutations in platelets.
Overall, there is general agreement that 10–30% of all ET
patients are wild type for JAK2, CALR and MPL mutations when the
molecular analyses are performed with DNA from isolated
granulocytes or peripheral blood.1 This subgroup of patients,
called ‘triple-negative’ (TN), has not been extensively studied with
regard to the presence of JAK2, CALR and MPL mutations in
platelets and RNA from granulocytes.
Recently, atypical mutations of MPL and JAK2 were identified by
whole-exome sequencing in a proportion of TN ET patients (10–
20%), suggesting that this group of patients represent a
heterogeneous disease category.7,8
We have characterised the molecular profile of a group of TN ET
patients by determining JAK2, CALR and MPL mutational profile
using RNA from platelets. Furthermore, we have assessed the
presence of additional mutations in JAK2 and MPL and other non-
driver genes by targeted next-generation sequencing (NGS) in
granulocytes.
A total of 35 triple negative ET patients (14.8% from the whole
cohort of 236 ET) diagnosed at the Haematology Department from
the Hospital del Mar were included in the study. The diagnosis of
ET was established according to WHO criteria.9 At the time when
platelet analysis was performed patients were not receiving
citoreductive therapy. The study was approved by the local Ethics
Committee and informed consent was provided according to the
Declaration of Helsinki.
All patients had been routinely assessed for mutations in DNA
from purified granulocytes. JAK2V617F was determined by quanti-
tative allele-specific PCR, MPL exon 10 mutations (W515, S505) were
analysed by Sanger sequencing and CALR exon 9 mutations were
analysed by PCR followed by fragment analysis as previously
described.10–12
RNA was extracted from platelets or granulocytes with Trizol
(Life Technologies, Carlsbad, CA) and 1 ug total RNA was reverse
transcribed. The mutational analysis of JAK2V617F was performed
by quantitative allele-specific real time PCR with probes specific
for the mutated and the wild-type form as described previously.10
Analysis of exon 10 of the MPL gene (S505, W515) was performed by
NGS (454 GS Junior, Roche Applied Science, Mannheim, Germany),
with a median coverage of 1335x (range 497–4863). Mutations were
confirmed by competitive allele specific TaqMan (CAST)-PCR assays
(Life Technologies). The mutational analysis of exon 9 of the CALR
gene was performed by PCR, using a 6-carboxyfluorescein labelled
reverse primer, followed by fragment analysis in a Genetic Analyser
3500DX (Applied Biosystems, Foster, CA, USA) or by NGS deep
sequencing (454 GS Junior, Roche Applied Science) with a median
coverage of 1326.5x (range 607–1686). In those patients in whom a
mutation was observed in platelets, we extracted RNA from
granulocytes to assess the presence of the mutation in these cells.
Screening for additional somatic mutations was performed by
targeted NGS in DNA extracted from purified granulocytes. All
mutations detected were confirmed by Sanger sequencing.
Clonality based on X chromosome inactivation pattern by
HUMARA was also analysed.
The main clinical and biological characteristics of the patients
are shown in Table 1. As can been seen, with a median follow-up
of 7 years (range: 0–27), 4 (11.4%) patients presented thrombotic
events and 4 (11.4%) haemorrhagic events during the evolution.
Table 1. Clinical and biological characteristics in 35 patients with
triple-negative essential thrombocythaemia
Age (years)a 58 (9–86)
Gender (M/F) May-30
Haemoglobin (g/l)a 137 (109–166)
Haematocrit (%)a 41 (34.2–51.8)
Platelet count (×109/l)a 669 (493–2700)
Leucocyte count (×109/l)a 8.5 (5–22.7)
Clonality by HUMARAb, n (%) 6 (24)
Cardiovascular risk factors
Smoking, n (%) 7 (20)
Hypertension, n (%) 14 (40)
Dyslipidaemia, n (%) 12 (34.3)
Diabetes mellitus, n (%) 6 (17.1)
Thrombosis before diagnosis, n (%) 6 (17.1)
Thrombosis during follow-up, n (%) 4 (11.4)
Major bleeding before diagnosis, n (%) 0 (0)
Major bleeding during follow-up, n (%) 4 (11.4)
Haematological and clinical information was collected at diagnosis;
information regarding major thrombosis and haemorrhage included
events after diagnosis. aMedian (range). bInformative in 25 female patients.
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No cases of transformation to acute leukaemia or secondary
myelofibrosis occurred.
Platelet analysis of JAK2, MPL and CALR showed the presence of
JAK2V617F in 2 out of 35 (5.7%) patients analysed, with allele
burdens of 16 and 20%. Regarding mutations in MPL gene,
analysis of exon 10 by NGS showed MPLW515L in three cases with
an allele burden of 2.16, 12 and 26% in platelets (Table 2). These
results were confirmed by independent PCR amplifications and
NGS sequencing runs. Interestingly, we detected the coexistence
of JAK2V617F and MPLW515L in two cases. No mutations in CALR
were detected in the analysis of platelet RNA by fragment analysis
or NGS.
Next, we also assessed whether these mutations could be
detected in granulocytic RNA. We demonstrated the presence of
three of these five mutations also in granulocytes when RNA was
analysed (Table 2). These results suggest that RNA expression of
mutant cells is higher than that from wild type cells, thus
improving the detection rate, when compared with analysis of
DNA. Furthermore, analysis of granulocyte DNA using commercial
CAST-PCR assays that increase mutation detection by blocking
amplification of the wild type allele, confirmed the presence of the
MPL mutation in granulocytes in the two patients with higher
allele burden. In the same way, applying Larsen assay in
granulocytic DNA,13 we confirmed JAK2V617F in the two patients
with allele burdens below 2% (Table 2).
Concerning the mutant allele burden, the JAK2V617F percen-
tage was higher in platelet RNA, than in granulocytes in the two
patients with the JAK2 mutation (Table 2). These results are in
agreement with our previous work comparing JAK2V617F allele
burden in platelets and granulocytes.6 Regarding MPLW515L, the
allele burden was higher in platelet RNA in two of the three
mutated patients (Table 2).
Since the detection of a molecular marker is a key element in ET
diagnosis and, moreover it may provide additional information
regarding the clinical outcome, studies in RNA obtained from
platelets and/or granulocytes might be useful in those patients
lacking a molecular marker in DNA from granulocytes. To the best
of our knowledge, this is the first study evaluating the mutational
status of JAK2, MPL and CALR in platelets from TN ET patients. Our
results show that 3 out of 35 (8.6%) TN ET patients presented a
driver molecular marker when the analysis was performed in
platelets.
To gain further insight in the molecular profile of the TN cases
we performed targeted NGS mutational analysis in granulocytes
from 29 out of the 35 patients included in the study. Overall, we
detected 14 additional mutations in 8 (27.6%) patients. Targeted
sequencing of JAK2 and MPL showed the presence of mutations in
exon 4 of the MPL gene in 4/29 (13.8%) patients (Table 2). In three
cases the mutations affected the amino acid Ser204: p.S204P
(n= 2) and p.S204F (n= 1), previously described by other groups.7,8
In the fourth patient a p.P222S was detected which has not been
previously reported. We did not find any JAK2 mutation variant. In
addition, mutations in TET2 (n= 5), CBL (n= 2), SF3B1 (n= 1) and
SH2B3 (n= 1) were observed (Table 2). These results support the
molecular complexity and heterogeneity of TN ET patients.
Interestingly, as shown in Table 2, a somatic mutation in either
driver or non-driver genes was detected in all patients who
presented monoclonal haematopoiesis assessed by HUMARA
analysis (6/25, 24%).
In summary, our results reinforce that TN ET patients represent a
heterogeneous group of patients in whom the performance of
molecular analysis in platelets together with targeted sequencing
by NGS techniques provide evidence of clonal hematopoiesis in
one-third of patients.
Table 2. Molecular abnormalites detected in 11 triple-negative essential thrombocythaemia patients
Patient JAK2 p.V617F allele burden (%)a MPL p.W515L allele burden (%) Additional mutations by NGS
in DNA from GR (allele burden)
HUMARA
RNA
platelets
RNA GR DNA GR RNA
plateletsb
RNA GRb DNA GRc
1 20 0 1.85 2.16 0 0 ND Clonal
2 16 10 1.8 12 33 Positive ND NA
3 0 26 15 Positive ND NA
4 0 0 MPL p.Pro222Ser (42.32%) Clonal
5 0 0 MPL p.Ser204Pro (46.94%) Clonal
6 0 0 TET2 p.Gln958Ter (20.17%) Clonal
TET2 p.Leu1880Pro1 (15.2%)
CBL p.Leu380Pro (2.79%)
7 0 0 MPL p.Ser204Phe (25.69%) Clonal
8 0 0 MPL p.Ser204Pro (37.45%) Clonal
MPL p.Arg592Gln (30.56%)
SF3B1 p.His662Asp (3.44%)
9 0 0 TET2 p.Gln790Ter (20%) No clonal
10 0 0 TET2 p.Ser1848Ter (44.74%) NA
SH2B3 p.Trp364Ter (41.47%)
CBL p.Val363Gly (3.69%)
11 0 0 TET2 p.Ala1196Asp (2.41%) NA
Abbreviations: GR, granulocytes; NA, not available. aJAK2 V617F was determined by allele-specific real time PCR. bDetermined by NGS. cDetermined by
CAST-PCR.
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